Title:
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
Phase:
III
Contact:
Elisabeth Lawrence / Kontaktperson
Clinical Investigator:
Dr. med. Sebastian Martin Thomas Dieter
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT06750094
EU CTIS/EudraCT:
Keine Registernummer angegeben. N/A: